American Society of Clinical Oncology (ASCO) Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Guideline Summary

QualityTool

American Society of Clinical Oncology (ASCO) Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: Guideline Summary

Description

The American Society of Clinical Oncology (ASCO) convened an expert panel to conduct a systematic review of the literature available through February 2004 on the use of sentinel lymph node biopsy (SNB) in early-stage breast cancer. This three-page tool summarizes the guideline recommendations developed by ASCO.

This guideline summary addresses the following topics:

  • Recommendations
    • How should the results of SNB be utilized in clinical practice? Can full axillary lymph node dissection be avoided in patients who have negative findings on SNB?
    • Is full axillary lymph node dissection necessary for all patients with positive findings on SNB?
    • What is the role of SNB in special circumstances in clinical practice?
  • Caution
    • What factors affect the success of SNB?
    • What are the potential benefits and harms associated with SNB?
  • Methodology
  • Limitations of the guideline

Developer:

American Society of Clinical Oncology

Funding Sources:

American Society of Clinical Oncology

History

Release Date: 2005
Original Summary: April 2006
Last Updated: 04/10/13

QualityTool Classification

Disclaimer: The inclusion of a tool in the Innovations Exchange does not constitute or imply an endorsement by the U.S. Department of Health and Human Services, the Agency for Healthcare Research and Quality or Westat of the tool or of the submitter or developer of the tool. Read more.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.